BioPharmSignal logoBioPharmSignal

Biotech News

Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

Twist Bioscience Corporation (TWST)Twist Bioscience CorporationEarnings

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 12, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025 .

Related news

TWSTTwist Bioscience Corporation2026-02-02 12:15 EST

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

TWSTTwist Bioscience Corporation2026-08-03 11:15 EST

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

View all latest news

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 20:01 EST

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 12:00 EST

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

TWSTTwist Bioscience Corporation2026-08-03 11:15 EST

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

TWSTTwist Bioscience Corporation2026-07-15 12:00 EST

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Stock data

Close
145.59 USD
Market cap
4.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States